Overview

RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode

Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The study is a phase II, double-blind, randomized, placebo controlled, parallel, multicentric study in 110 patients with drug resistant depression.
Phase:
Phase 2
Details
Lead Sponsor:
Mapreg
Treatments:
Antidepressive Agents